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ABSTRACT
Immunotherapy is an effective treatment in advanced cancer, although predictors of response are
limited. We studied whether excess weight influences the efficacy outcomes of immunotherapy. We
have also evaluated the combined prognostic effect of excess weight and immune-related adverse
events (irAEs).
Efficacy of anti-PD-1 treatment was evaluated with both objective radiological response (ORR) rate
and progression-free survival (PFS), and toxicity with irAEs. We studied the association between excess
weight and ORR, PFS or irAEs.
132 patients diagnosed with advanced cancer were included. Median body mass index (BMI) was 24.9 kg/
m2. 64 patients had normal weight (BMI<25 kg/m2), and 64 patients had excess weight (BMI≥25 kg/m2). Four
patients had underweight and were excluded from further analysis. ORR was achieved in 50 patients (38.0%),
median PFSwas 6months. 44 patients developed irAEs (33.3%). ORRwas higher in excess weight patients than
in patients with normal weight (51.6% vs 25.0%; OR 3.45, p = .0009). PFS was improved in patients with excess
weight (7.25 months vs 4 months, HR 1.72, p = .01). The incidence of IrAEs was not different in patients with
excess weight (54.5% vs 43.2%, p = .21). When high BMI and irAEs were combined, we observed a marked
prognostic trend in ORR rate (87.5% vs 6.2%; OR 161.0, p< .00001), and in PFS (14months vs 3months; HR 5.89,
p < .0001).
Excess weight patients with advanced cancer that receive single-agent anti-PD-1 antibody therapy
exhibit a significantly improved clinical outcome compared with normal BMI patients. This association
was especially marked when BMI and irAEs were considered combined.
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A general adverse impact of excess weight (BMI ≥ 25 kg/m2) in
the general population has been recognized in recent years.1–4
Cancer patients with excess weight may also have a worse overall
prognosis compared to patients with normal Body Mass Index
(BMI), 5–11 and some studies have suggested that excess weight
may be related to a worse response to conventional therapies, 12–14
although this has not always been confirmed.6,15-18
A recent report has suggested that there is a paradoxical effect
of obesity on immunotherapy-treated cancer, because there is an
improved antitumor efficacy after checkpoint blockade.19 The
authors suggested that this might be related to a direct targeting
of some of the pathways activated in obesity. In a group of
patients with advanced melanoma, a significant improvement
of response to checkpoint inhibitors was also reported in
patients with BMI above normal.20,21 This surprisingly positive
association between obesity and the efficacy of cancer immu-
notherapy has been recently recognized, and the need for further
studies and the understanding of the underlying immunological
principles has been highlighted.22
The aim of our study was to evaluate the association
between excess weight and cancer immunotherapy outcome
and toxicity in patients with advanced solid and hematological
tumors treated with anti-PD-1 immune checkpoint inhibitors.
We used the objective radiological response (ORR) and pro-
gression-free survival (PFS) as efficacy outcomes. Since we
have recently reported that immune-related adverse events
(irAEs) in patients treated with anti-PD-1 drugs is directly
related to the response and an increase in PFS, 23 we also
evaluated the influence of the development of irAEs in terms
of ORR and PFS in the cohort of excess weight or normal
weight patients.
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Results
Patient characteristics
One hundred and thirty-two patients were studied. Median
age was 69 y (32–86 y); 95 patients were male (71.9%) and
103 (79.2%) were smokers at diagnosis. Patients’ malignan-
cies were non-small-cell lung cancer (NSCLC) in 93 cases
(56 non-squamous, 33 squamous and 4 non-specified),
melanoma in 12, squamous cell carcinoma of head and
neck (SCCHN) in 9, clear cell renal carcinoma in 6, urothe-
lial bladder carcinoma in 4, Hodgkin lymphoma (HL) in 3
cases, gastric carcinoma in 2 cases, and gallbladder adeno-
carcinoma, merkel cell carcinoma and hepatocellular carci-
noma, 1 case each. All selected patients had advanced or
metastatic disease. ECOG performance status (PS) was 0–1
in 92 patients (75.1%), and 2 in 40 (24.9%). No patient had
ECOG PS 3 or 4. Median follow-up was 6 months (0.5–-
32 months). PD-L1 expression was available for 41 cases, 35
of which had a positive result. Twenty of these positive
samples had high PD-L1 expression (PD-L1 ≥ 50%:
48.7%). Patients’ median weight was 70 (42–102) kg and
median BMI was 24.9 (14.8–37.1) kg/m2. Sixty-four
patients had normal BMI (18.5–25 kg/m2), and 64 patients
had excess weight (BMI ≥ 25 kg/m2). Of these, 18 patients
were obese (BMI ≥30 kg/m2).
The distribution of comorbidities between excess weight
and normal weight patients is shown in Table 1.
Treatment and clinical outcomes
Ninety-four patients were treated with nivolumab and 38 with
pembrolizumab. Twenty-six patients (19.7%) received anti-
PD-1 treatment as first-line therapy, 56 patients
(42.4%) second line, 26 patients (19.7%) third line, 18 patients
(13.6%) fourth line, 4 patients (3.0%) fifth line, 1 patient
(0.8%) sixth line and 1 patient received anti-PD-1 treatment
as ninth line therapy. All patients with HL had previously
received bone marrow transplant, two of them including
allogenic bone marrow transplant.
Objective radiological response was observed in 50 patients
(38.0%): complete response in 5 cases (3.8%) and partial
response in 45 (34.1%). Stable disease was detected in 37
cases (28.0%) and progressive disease in 45 cases (34.1%).
Median PFS was 6 months (0.5–36 months).
Forty-four patients (33.3%) developed irAEs, making
a total of 60 events occurring at a median time of 6 weeks
(range 2–24) from the begining of the treatment.
Hypothyroidism was the most frequent irAE observed
(n = 22 events, 14 cases grade 1, 4 cases grade 2 and 4 cases
grade 3), followed by immune-mediated nephritis (n = 7, 2
cases in grade 1, 2 cases in grade 2 and 3 cases in grade 3),
hyperthyroidism (n = 6, 1 case in grade 1 and 5 cases in
grade 2), pneumonitis (n = 5, all grade 1), rash (n = 3, all
grade 1), immune-mediated hepatitis (n = 3, 1 case in grade 1
and two in grade 4), arthritis (n = 3, 2 case in grade 2 and 1
Table 1. Characteristics and differences between excess weight and normal BMI.
Excess Weight
(N = 64) Normal BMI (N = 64) P value
Age, median 69 68.5 P = .77
Sex
Female 19 (29.7%) 17 (26.5%) P = .76
Male 45 (70.3%) 47 (73.5%)
Treatment
Nivolumab 43 (67.1%) 49 (76.5%) P = .27
Pembrolizumab 21 (32.9%) 15 (23.5%)
Histology
(two most frequent) Adenocarcinoma 26 (40.6%) 29 (45.3%) P = .50
Squamous carcinoma 20 (31.2%) 22 (34.3%)
ECOG PS
ECOG 0 9 (14.1%) 8 (12.5%) P = .09
ECOG 1 41 (64.1%) 30 (46.9%)
ECOG 2 14 (21.8%) 26 (40.6%)
Smoking habit
Currently smokers 48 (75%) 53 (82.8%) P = .45
Non smokers 15 (25%) 11 (18.2%)
Prior lines treatment
No prior lines 16 (25%)
9 (14.1%) P = .38
One prior line 26 (40.6%) 28 (43.7%)
Two or more prior lines 22 (34.4%) 27 (42.2%)
Immune-related Adverse Events
Yes 24 (37.%) 19 (29.7%) P = .21
No 40 (62.5%) 45 (70.3%)
Hypertension
Yes 37 (57.8%) 19 (29.7%) P = .001
No 27 (42.2%) 45 (70.3%)
Diabetes Mellitus
Yes 9 (14.1%) 12 (18.7%) P = .47
No 55 (85.9%) 52 (81.3%)
Corticosteroid consumption
Yes 14 (21.9%) 7 (10.9%) P = .09
No 50 (78.1%) 57 (89.1%)
* BMI: Body Mass Index
* ECOG PS: Eastern Cooperative Oncology Group Performance Status
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case in grade 3); panhypopituitarism (n = 2, grade 1),
immune-mediated colitis (n = 2, grade 2 and grade 3) hypo-
physitis (n = 1, grade 1), adrenal insufficiency (n = 2, grade 1),
diabetic ketoacidosis (n = 1, grade 4), myositis (n = 2, grade 2)
and encephalitis (n = 1, grade 4). Nine of the 44 patients who
developed irAEs stopped treatment due to unacceptable toxi-
city (20.4%): one patient for grade 3 colitis, three patients for
grade 3 nephritis, two patients due to hepatitis grade 3 and 4,
respectively, one patient with grade 3 arthritis, one patient
with grade 4 diabetic ketoacidosis and one patient due to
grade 4 encephalitis. Twenty-one patients from the total
cohort received treatment with a minimum dose of
0.5–1 mg/kg of methylprednisolone due to severe irAEs devel-
opment or as anti-inflammatory therapy. None of the patients
were not receiving corticosteroids at baseline or during the
2 months before the start of immunotherapy.
Twenty-four of the 44 patients with irAEs had excess weight
(54.5%) versus 19 of the 44 patients (43.2%) that had a normal
BMI (p = .39); as is the same: 24 patients with excess weight
(37.5%) presented an irAE versus 19 patients with normal BMI
(29.7%). Table 1. Thirty-nine of the 88 patients without treat-
ment-related toxicity were patients with excess weight (44.3%),
compared to 46 patients (52.2%) with normal BMI (p = .31).
The clinical characteristics and outcome of the four patients
with underweight that were excluded of the analysis were the
following. All met criteria of cachexia. All had lung cancer
(three non-squamous, one squamous). Their median age was
60 y. Three patients were male. Three patients received treatment
with nivolumab and one received pembrolizumab. Two patients
developed irAEs (both hypothyroidism) and one patient obtained
an objective response, with a median PFS of 5.5 months.
Excess weight and treatment efficacy
Thirty-three of the 64 patients with excess weight presented
ORR to anti-PD-1 antibodies (51.6%), compared to 16 of the
64 patients (25.0%) who presented normal BMI (OR 3.45, CI
95% 1.58–7.55, p = .0009). Patients with excess weight had
therefore more than 3 times greater probability of obtaining
an objective response (ORR) compared to normal weight
patients (Table 2). We analyzed separately the efficacy in
obese or overweight patients: 8/18 obese patients obtained
ORR (44.4%) and 25/46 in overweight patients
(54.3%) (p = NS).
Regarding progression-free survival, patients with excess
weight had higher PFS compared to those with normal BMI:
7.25 vs 4 months of median PFS (long Rank p = .007).
Significant differences were still observed even after adjust-
ment for sex, histology, smoking habit, prior treatments
received, type of anti-PD-1 antibody received, ECOG func-
tional status and all the clinical and demographic variables
studied (HR 3.77, CI 95% 1.33–10.66, p = .01). Figure 1.
Excess weight, irAEs and treatment efficacy
Twenty-one of the 24 patients who presented both irAEs and
excess weight simultaneously presented ORR (87.5%), compared
to only 3 of the 48 patients (6.2%) who did not present either
toxicity or excess weight (OR 161.0, CI 95% 4.95–5.23e + 03,
p < .00001) or to 11 of the 39 patients with excess weight who
did not develop irAEs (28.2%) (OR 9.03, CI 95% 1.67–48.71,
p = .001).
Excess weight patients who also developed irAEs had
a benefit in terms of PFS, compared to those who did not
Table 2. Relationship of objective radiological response (ORR) and excess weight





ORR 33 (51.5%) 16 (25%) P < .001
No ORR 31 (48.5%) 48 (75%)
* ORR: Objective radiological response
Figure 1. Median progression-free survival according to BMI.
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have irAEs and who had normal BMI: 14 vs 3 months (log-
rank p < .00001). Differences were still statistically significant
even after adjusting for sex, histology, smoking habit, prior
lines treatment, type of anti-PD-1 antibody received, ECOG
functional status and all the clinical and demographic vari-
ables studied (HR 5.89, CI 95% 2.77–13.05, p < .0001).
Figure 2.
Multivariate analysis showed significant differences when
comparing patients with excess weight who developed irAEs
versus those without excess weight who also developed irAEs,
with higher PFS for the first group: 14 vs 10 months (HR
12.29, CI 95% 2.8–53.8 p = .01). Figure 2.
For patients who did not develop irAEs, PFS was 6 months for
those with excess weight versus 3 months in individuals with
normal BMI (log-rank 0.007). Multivariate analysis in this setting
showed a trend toward significance (HR 2.41, CI 95% 0.70–-
8.31, p = .16).
Discussion
Our study confirms the observation that there is an associa-
tion between excess weight and anti-PD-1 immunotherapy
outcome in patients with advanced cancer, and also expands
it by finding that combining BMI with irAEs identifies dis-
tinctive predictive groups. We had recently shown that irAEs
were associated with a favorable outcome in cancer patients
treated with immune-checkpoint inhibitors (ICIs), 23 and now
we show that those patients with excess weight who also
develop irAEs have a dramatic probability of achieving
a response and having longer PFS compared to those patients
with normal BMI and no irAEs. Very relevantly, the develop-
ment of irAEs and the presence of excess weight were inde-
pendent predictors of clinical benefit to anti-PD-1 immune
checkpoint inhibitors, and in our cohort, we also observed
that excess weight did not influence the development of irAEs.
The BMI data analysis in our series confirms the results of
recent studies, in which the benefit and efficacy of treatment with
immune checkpoint inhibitors was related to BMI.20,21 In contrast
to our study, these published studies either considered amixed use
of immunotherapy drugs (that included anti-CTLA-4 antibodies)
or studied patients with a single type of malignancy. One of these
studies is a retrospective series published with a total of 76 patients
from three hospitals in Austria.20 Patients were diagnosed with
melanoma and were treated with a single anti-CTLA-4 drug
(ipilimumab). In this study, patients were stratified into two
cohorts according to their BMI. They observed that those with
a BMI≥25 kg/m2 presented high response rates (p = .024, chi-
square), although only with a significant trend in the multivariate
analysis (OR 2.75, CI 95% 0.87–8.66, p = .084). They found no
significant differences in PFS (p = .924, log-rank), or OS (p = .056,
log-rank).20 Another study analyzed BMI in an extensive cohort of
patients diagnosed with advanced melanoma, treated with the
immunotherapy drugs ipilimumab, pembrolizumab, nivolumab
or atezolizumab.21 Although associations were observed, the mul-
tivariate analysis found that excess weight were associated to
a better PFS or OS only in male patients. A similar finding was
also observed in patients treated with targeted therapy, but not in
those treated with chemotherapy. These authors did not evalu-
ate ORR.
Murphy and Longo22 have suggested that obesity could be
considered as a positive prognostic factor for treatment with
immune checkpoint inhibitors (ICIs) due to its mechanism of
action. ICIs are drugs that boost our immune system, so in
cases where obesity preexists, their action may be favored by
the proinflammatory status of these obese patients. In our
study, excess weight patients had a better immunotherapy
effect, and this was more pronounced in those patients that
developed irAEs, and these two clinical characteristics have
been associated with a greater proinflammatory response.
Wang et al.19 reported an analysis of a prospective cohort
of 250 patients diagnosed for multiple cancers receiving treat-
ment with anti-PD-1. They showed improved PFS (8 vs
4.7 months, p = .003) and overall survival (17.4 vs 12 months,
p = .04) in patients with obesity, although no data for ORR
Figure 2. Median progression-free survival according to BMI and development of irAEs.
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were reported. They attributed their findings to a significant
increase in the expression of PD-1 in obese patients diagnosed
with melanoma in another arm evaluated in this work, 19 and
suggested that the proinflammatory state of obesity create an
excess production of leptin, entails an aging of T lymphocytes
and leads to this overexpression of PD-1, allowing a greater
beneficial response to anti-PD-1 therapies.22 Our study
included patients with several types of malignancies, and we
evaluated a single class of immune checkpoint inhibitors, i.e.
anti-PD-1, allowing possibly a more consistent interpretation
of the findings observed.
To our knowledge, this is the first time in which excess
weight is explicitly found to be a predictor of better outcome
in patients with several types of tumors receiving treatment
with anti-PD-1, and that this effect is enhanced in the pre-
sence of irAEs. IrAEs have been related to anti-PD-1
outcome,23 but, again, there is no previous research that
shows that the association between irAEs and excess weight
further enhances the effectiveness of anti-PD-1 immune
checkpoint inhibitors, supporting the synergistic effect that
has been seen in our study. We believe that our findings
have particular clinical relevance because we demonstrate
that the benefit to the same type of anti-PD-1 treatment is
increased in all types of advanced cancer when patients
present the two characteristics studied in our work. It
might be considered that including in the study two patients
diagnosed with HL treated with nivolumab and one patient
diagnosed with Merkel cell carcinoma treated with pembro-
lizumab might be a limitation due to better outcome of these
histologies in the pivotal studies.24,25 Although the 2 HL
patients were in a worse disease stage than patients at the
clinical trial.
Conclusion
We show that excess weight is associated with a greater prob-
ability of a favorable treatment outcome in patients with
advanced cancer who receive immunotherapy single-agent
anti-PD-1 antibodies nivolumab or pembrolizumab, and that
when irAEs develop in excess weight population the observed
therapeutic benefit is further enhanced. Developing
a prospective evaluation to confirm our findings is necessary.
Such a prospective study should include more precise meth-
ods to measure of excess weight, like the hip circumference.
Material and methods
Study design and patients
We performed an observational cohort study where we fol-
lowed patients starting treatment with anti-PD-1 drugs pem-
brolizumab or nivolumab. Thus, we carried out
a retrospective review of all clinical records of patients diag-
nosed with advanced cancer and treated with single-agent
anti-PD-1 drugs pembrolizumab or nivolumab, from
January 2016 to December 2018, at the Hospital
Universitario de La Princesa. Patients weight was classified
according to WHO and NIH criteria26,27 using BMI.
Underweight was BMI less than 18.5; normal weight, BMI
18.5 to 24.9; overweight, BMI 25 to 29.9; and obese, BMI 30 or
more. Overweight and obese patients were considered
together and defined as excess weight patients. Underweight
patients met criteria of cachexia in all cases and were excluded
from the study due to reports of poorer response detected in
previous studies.28
Treatment efficacy was measured using ORR (immune
RECIST criteria) and PFS.29 IrAEs were defined according
to criteria reported in previous studies,23 and their grade
was established following to the Common Terminology
Criteria for Adverse Events version 4.0 (CTCAE-4.0).
All patients were followed from the start date of treatment
until 31st of March of 2019 or until patient death or last date of
follow-up. A baseline laboratory test was performed according to
routine clinical practice. After treatment was started, clinical and
laboratory tests were carried out every 2 weeks in patients
receiving Nivolumab or every 3 weeks in patients receiving
Pembrolizumab, prior to drug administration. Body CT-scans
were performed every 8–12 weeks or as clinically indicated. The
dose of pembrolizumab was 200 mg as fixed dose every 21 d if it
was a first-line treatment, or 2 mg/kg every 21 d if it was
prescribed as second line or beyond. The dose of nivolumab
was 3 mg/kg every 14 d in all cases. The study was approved by
the Ethics and Research Committee of Hospital Universitario de
la Princesa. All patients signed a written informed consent
before being included in this study.
Statistical analysis
Descriptive data are reported as relative frequencies for dis-
crete variables. Continuous variables are reported as mean ±
standard deviation (SD) or median and interquartile range
(IQR) for normal and not normally distributed variables,
respectively. To determine the association between weight
and ORR, Chi-square Test and Odds Ratio were performed.
To determine the relationship between the presence of asso-
ciation of adverse immune-mediated events in patients with
excess weight and the achievement of ORR, Chi-square Test
and Odds Ratio were also performed. The association
between excess weight alone and excess weight plus irAEs
development with the PFS, were analyzed with log-rank test
and multivariate Cox regression analysis, adjusted by sex,
histology, smoking habit, prior lines treatment, type of anti-
PD-1 antibody received, functional status as measured by the
scale of the Eastern Cooperative Oncology Group (ECOG)
and all the clinical and demographics variables studied.
Kaplan–Meier curves showing PFS according to development
or not of irAEs depending on the presence of overweight
were estimated. Statistical analyses were carried out with
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